Optiglobin (Human Normal Immunoglobulin)

Optiglobin is an immunoglobulin replacement therapy that acts on the humoral immune system to restore antibody levels.

• Primary immunodeficiency diseases: provides the missing antibodies to reduce infection frequency.
• Secondary immunodeficiency (e.g., chronic lymphocytic leukemia): supplies antibodies to help prevent opportunistic infections.
• Post‑exposure prophylaxis for certain viral infections: offers passive immunity until active immunity develops.

• Optiglobin contains pooled human IgG antibodies that bind to a broad range of antigens. After intravenous infusion, the antibodies distribute throughout the vascular and extravascular compartments, neutralising pathogens, opsonising microbes for phagocytosis and modulating complement activation, thereby restoring humoral immunity in patients with antibody deficiencies.

Adverse reactions may range from mild infusion‑related events to rare systemic complications.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Fever or chills: typically occurring during or shortly after infusion.
• Nausea or vomiting: occasional gastrointestinal discomfort.
• Injection site erythema: localized redness at the infusion site.
• Fatigue: generalized tiredness following administration.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Aseptic meningitis: rare inflammatory response of the meninges.
• Acute renal failure: sudden loss of kidney function, observed in very few cases.
• Thromboembolic events: clot formation that can affect circulation.
• Hemolytic anemia: destruction of red blood cells leading to anemia.

Before initiating Optiglobin therapy, clinicians should assess patient history and monitor for potential complications.

• Renal function: evaluate baseline creatinine and adjust infusion rate if impaired.
• Cardiovascular status: monitor blood pressure and heart rate during infusion.
• History of allergic reactions: screen for prior IgG product intolerance.
• Concomitant anticoagulants: observe for bleeding tendencies.
• Pregnancy and lactation: weigh benefits against potential risks.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Optiglobin may interact with other agents that affect immune function or coagulation.

Major Interactions (Avoid)

• Live vaccines: concurrent use can diminish vaccine efficacy and increase adverse events.
• High‑dose immunosuppressants (e.g., rituximab): may reduce the therapeutic benefit of administered IgG.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, DOACs): monitor coagulation parameters for altered bleeding risk.
• ACE inhibitors: observe for increased incidence of hypotensive reactions during infusion.
• Diuretics: watch for volume overload or electrolyte shifts.
• Cytotoxic chemotherapy: assess infection risk and adjust dosing schedule as needed.